Program
SAR448851
A development code.
In Sanofi’s pipeline, TREM2 agonist
. Its studies are mostly in Alzheimer Disease, led by Sanofi.
Furthest: phase 2, since Jun 30, 20261 company-led study, 1 open or runningNext primary completion: Jul 31, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 2since Jun 30, 2026 | Jun 30, 2026 | Jul 31, 2029phase 2 · NCT07688213 |
- Named in Sanofi’s own pipeline as
SAR448851
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2026First study: phase 2 study in Alzheimer DiseaseFirst studyNCT07688213 · 160 planned · United States, Australia, Canada and more
Ahead
- Jul 31, 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07688213
TargetBeta
“TREM2 agonist”the company's pipeline, read by Claude · source
Other programs on TREM2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-TREM2 Monoclonal Antibody EOS006215rule | iteos-belgium-sa | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07688213Alzheimer Disease · United States, Australia, Canada and more | 2 | Recruiting | Jul 31, 2029 | 160 |
How it is read
Names in the registry
- “SAR448851”, 1 entry
Codes read as this program: SAR448851.
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.